leisure time -WSS

leisure time

author：comprehensive 2025-09-27 12:57:04 - browse：56

AI skin cancer detector, dermasensor. -- health tech coverage from STAT — Around 5 million skin cancers are diagnosed each year in the United States. Skin cancer is common, but it’s also not that deadly when caught early. Courtesy DermaSensor

The Food and Drug Administration cleared an AI-powered device for detecting skin cancer on Wednesday, giving primary care physicians a new way to evaluate troubling skin spots.

Around 5 million skin cancers are diagnosed each year in the United States. Skin cancer is common, but most types are not that deadly when caught early.

The device, developed by a small company called DermaSensor, is handheld and uses light to examine suspicious moles on a cellular level. It will be marketed specifically for primary care physicians to use in routine check-ups in patients aged 40 and above.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Fetal surgery at risk from Dobbs and new abortion restrictions

entertainment

WSS

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Takeda, Janssen join wearable maker to measure scratching

The EPA's new lead rule: How one expert crunched the numbers

CDC director unscathed in first congressional testimony

J&J to emphasize cancer drugs, stop much of its vaccine research

Nobel honors Karikó and Weissman's enduring partnership

hotspot

leisure time

Wikipedia

Jerome Adams on the need for new antivirals for Covid

Stop Congress from blocking public access to science

Trump demands the U.S. pay no more for drugs than other countries … again

Fetal surgery at risk from Dobbs and new abortion restrictions

Medical records are filled with copy

Study points to new risk in gene therapy death of Terry Horgan

Wildfire smoke exposes gaps in outdoor worker protections

The EPA's new lead rule: How one expert crunched the numbers

Psychedelics group wrestles with new pharma identity

Congress extends some pandemic preparedness programs

focus

ReNAgade cuts staff seven months after raising $300 million

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Diagnostic tests are hitting their mathematical limits

With clinical trial data readouts, here's how to spot spin

Congress extends some pandemic preparedness programs

30 years of 'Listening to Prozac'

hotspot

entertainment

knowledge

hotspot